A registered clinical trial update dated August 25, 2026 reports the status of study NCT01521923. The trial, titled "A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drugs (DMARD)-naïve Adults With Early Active Rheumatoid Arthritis," is a Phase 3 study. Its current status is listed as completed.
This update pertains to certolizumab pegol, not fragment 176-191, based on the registry record provided. The study evaluated certolizumab pegol in combination with methotrexate specifically in DMARD-naïve adults with early active rheumatoid arthritis. No efficacy or safety results are included in this update. The record reflects only the trial's design and its completed status as of the listed date.
Fragment 176-191 remains classified as an unapproved research compound. It is not the subject of this particular trial record. Readers interested in the broader research context for fragment 176-191 can consult the compound overview for additional background.